Ross-Macdonald, Petra https://orcid.org/0000-0001-5132-4396
Walsh, Alice M https://orcid.org/0000-0001-5905-5768
Chasalow, Scott D https://orcid.org/0000-0003-1513-0249
Ammar, Ron https://orcid.org/0000-0002-6006-7392
Papillon-Cavanagh, Simon https://orcid.org/0000-0002-0372-2266
Szabo, Peter M https://orcid.org/0000-0002-3684-135X
Choueiri, Toni K https://orcid.org/0000-0002-9201-3217
Sznol, Mario https://orcid.org/0000-0003-4137-9662
Wind-Rotolo, Megan https://orcid.org/0000-0001-8063-9928
Clinical trials referenced in this document:
Documents that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
Funding for this research was provided by:
Bristol-Myers Squibb Company